Over the past few years, substantial advances have been made in understanding the
pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and …

Overview Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast
cells (MCs) in extra‐cutaneous organs. Diagnosis The major criterion is presence of …

Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT
D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) …

Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-driven hematologic
neoplasm characterized by mast cell infiltration and shortened survival. We report the results …

Background Advanced systemic mastocytosis comprises rare hematologic neoplasms that
are associated with a poor prognosis and lack effective treatment options. The multikinase …

Systemic mastocytosis (SM) has greatly benefited from the broad application of precision
medicine techniques to hematolymphoid neoplasms. Sensitive detection of the recurrent KIT …

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy
characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic …

Disease overview: Systemic mastocytosis (SM) results from a clonal proliferation of
abnormal mast cells (MC) in one or more extra‐cutaneous organs. Diagnosis: The major …

Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm, driven by the KIT
D816V mutation in> 90% of patients. Avapritinib, a potent, highly selective D816V-mutant …

Overview Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast
cells (MC) in extra‐cutaneous organs. Diagnosis The major criterion is presence of …